What is Rheumatoid Arthritis?
Rheumatoid arthritis can occur at any age, but is more common in middle age. Women are more prone to the disease than men.
The exact cause of rheumatoid arthritis is unknown. Infection, genes and hormonal changes may be linked to the disease.
Rheumatoid arthritis leads to pain, swelling, stiffness and loss of function in the joints. Being a systemic disease, it tends to affect other organs in the body as well.
Rheumatoid arthritis progresses in 3 stages:
- Stage 1- Swelling of the synovial lining; causing pain, warmth, stiffness, redness and swelling around the joint.
- Stage 2- Rapid division and growth of cells, or pannus; which causes the synovium to thicken.
- Stage 3- The inflamed cells release enzymes that might damage bone and cartilage; often causing the involved joint to lose its shape and alignment, causing more pain and loss of movement.
Rheumatoid arthritis requires lifelong treatment with medications, physical therapy, exercise, education and surgery. Early, aggressive treatment can delay joint destruction.
What is New in Rheumatoid arthritis?
1. When Arthritis Flares Up, Drug Infused Hydrogel Will Become ResponsiveAnti-inflammatory drug loaded hydrogel started releasing the drug when the inflammation was triggered by arthritis-related enzymes which usually occurs in patients with arthritis, finds a new study. The findings of this study are published in the journal of APL Bioengineering. The drug-loaded hydrogel is designed in such a way that drug release is triggered by the activity of arthritis-related enzymes that are increased during arthritis flare episodes and when it is more severe, the locally injected hydrogel degrades more rapidly corresponding to increased effective drug release.Read More..
Latest Publications and Research on Rheumatoid ArthritisMultidimensional improvement in connective tissue disease-associated interstitial lung disease: Two courses of pulse dose methylprednisolone followed by low-dose prednisone and tacrolimus. - Published by PubMed
The patient perspective on biologic DMARD dose reduction in rheumatoid arthritis: a mixed methods study. - Published by PubMed
An Observational Study of Cardiovascular Risks Associated with Rheumatoid Arthritis Therapies: A Comparison of Two Analytical Approaches. - Published by PubMed
Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial. - Published by PubMed
Vimentin as antigenic target in autoimmunity: A comprehensive review. - Published by PubMed